In cancer patients, infusions of recombinant human IL-6 significantly increased activation markers of coagulation such as thrombin-antithrombin III complexes and prothrombin fragment F1 + 2, without substantially impacting fibrinolysis [31]. Here, IL6 is linked to cancer.